MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Rockwell Medical Market Cap 2011-2026 | RMTI
As of April 14, 2026 Rockwell Medical has a market cap of $ 33.8 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Rockwell Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.8 M | 29.2 M | 35.5 M | 20.5 M | 38.5 M | 86.2 M | 166 M | 153 M | 286 M | 282 M | 311 M | 447 M | 345 M | 131 M | 186 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 447 M | 20.5 M | 170 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.12 | 0.97 % | $ 43.9 M | USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.57 | -0.39 % | $ 1.35 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.72 | 2.14 % | $ 2.09 B | Canada |
 |
Harrow Health
HROW
|
1.93 B | $ 37.1 | 3.26 % | $ 1.36 B | USA |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.08 | 2.86 % | $ 116 M | Canada |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.42 | 1.43 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 7.38 | 1.23 % | $ 291 M | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
271 M | $ 4.33 | 1.41 % | $ 279 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.24 | 3.52 % | $ 422 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.37 | -3.52 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
1.19 B | $ 6.72 | 2.28 % | $ 4.15 B | Canada |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.38 | - | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 24.06 | 1.13 % | $ 1.11 B | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
108 M | $ 2.38 | - | $ 321 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 13.83 | 2.67 % | $ 16.6 B | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.75 | 9.54 % | $ 3.23 M | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 18.02 | - | $ 115 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 1.01 | 1.0 % | $ 50.4 M | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 8.39 | 4.61 % | $ 734 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.35 | 3.07 % | $ 2.92 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.65 | 0.6 % | $ 2.79 M |  China |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.05 | -0.97 % | $ 23.7 M | USA |